The group website lists TPD as a CRO service. Custom offerings explicitly cover target engagement, modulation, and degradation, plus custom proteins, cell lines, and assay development.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The group website lists TPD as a CRO service. Custom offerings explicitly cover target engagement, modulation, and degradation, plus custom proteins, cell lines, and assay development.
The service page explicitly describes high-throughput identification of polymorphs, salts, solvates, and cocrystals.
Biologics characterization, GMP testing, bioanalysis and clinical biomarkers
Specialist contract research/testing services
Program / service
Target / indication
Representative stage
Evidence & scope
Custom cellular and biochemical TPD assays and target degradation characterization
Program-dependent / not disclosed · Determined by the collaboration program
Platform / services
This record does not claim platform-wide human validation
Solid-state R&D capabilities
Determined by the submitted sample and research question · Not applicable; service capability
Services / platform
Not applicable; not a human clinical program
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
